Author |
Topic Search Topic Options
|
mainsailset
Senior Member
Joined: Jul 27 2008
Location: Washington State
Status: Offline
Points: 5004
|
Post Options
Thanks(0)
Quote Reply
Topic: Zometa(s) increase lifespan! Posted: Feb 03 2011 at 3:34pm |
New study indicates that the biophosphonates actually increase lifespan by 5 years! Wahoo!
Edited by mainsailset - Feb 03 2011 at 3:36pm
|
dx 7/08 TN 14x6.5x5.5 cm tumor
3 Lymph nodes involved, Taxol/Sunitab+AC, 5/09 dbl masectomy, path 2mm tumor removed, lymphs all clear, RAD 32 finished 9/11/09. 9/28 CT clear 10/18/10 CT clear
|
|
123Donna
Senior Member
Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 13509
|
Post Options
Thanks(0)
Quote Reply
Posted: Feb 03 2011 at 3:45pm |
Mainy,
Great news. I probably is due to the bone strengthening benefit and less falls among the elderly. Now only if we could see that type of benefit with women with bc!
Donna
|
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09) 11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15
|
|
outnumbered
Senior Member
Joined: Feb 02 2009
Location: New Jersey
Status: Offline
Points: 525
|
Post Options
Thanks(0)
Quote Reply
Posted: Feb 03 2011 at 5:46pm |
Wow, finally something positive that I can benefit from....
|
~Sara
DX @ age 40 6/24/08 Stage 1 Grade 3 BRCA1+ 187delAG
BMX (nipple-areola-sparing) 8/5/08
Redo BMX (remove nipple and areola) w/ Lat Flap 7/6/09
BSO 9/3/09
NED since 08/05/2008
|
|
dmwolf
Senior Member
Joined: Jan 22 2009
Location: Berkeley, CA
Status: Offline
Points: 3619
|
Post Options
Thanks(0)
Quote Reply
Posted: Feb 03 2011 at 6:22pm |
Wow, maybe the clodronate I swallow every morning is not for nothing! (Assuming I don't recur, which it might not help with). d
|
DX 2/08@43 stg II IDC; gr2,0 nodes. Neoadj chemo, first ACx2 (fail) then CarboTaxotereX6(better). Lump, Rads done 11/08; Clodronate. False alarm queen: PetCT lung & TM marker. NED. PBM w/recon 9/10.
|
|
dmwolf
Senior Member
Joined: Jan 22 2009
Location: Berkeley, CA
Status: Offline
Points: 3619
|
Post Options
Thanks(0)
Quote Reply
Posted: Feb 03 2011 at 6:24pm |
It's a very small study, so we probably shouldn't get too excited. d
|
DX 2/08@43 stg II IDC; gr2,0 nodes. Neoadj chemo, first ACx2 (fail) then CarboTaxotereX6(better). Lump, Rads done 11/08; Clodronate. False alarm queen: PetCT lung & TM marker. NED. PBM w/recon 9/10.
|
|
mainsailset
Senior Member
Joined: Jul 27 2008
Location: Washington State
Status: Offline
Points: 5004
|
Post Options
Thanks(0)
Quote Reply
Posted: Feb 03 2011 at 7:55pm |
Hey Denise old girl, itty bitty good news was all I could find this afternoon so put your feet up, have a cocktail and smile! Tomorrow I'm sure they'll tell us it was an early April Fool's joke, but for today, it's a Snoopy Dance time!
|
dx 7/08 TN 14x6.5x5.5 cm tumor
3 Lymph nodes involved, Taxol/Sunitab+AC, 5/09 dbl masectomy, path 2mm tumor removed, lymphs all clear, RAD 32 finished 9/11/09. 9/28 CT clear 10/18/10 CT clear
|
|
Julia
Senior Member
Joined: Jun 14 2009
Status: Offline
Points: 156
|
Post Options
Thanks(0)
Quote Reply
Posted: Feb 04 2011 at 6:01am |
Good news is good news, and I'll take any I can get. :)
|
Diag. 3/09 TNBC, IBC, 55mm.
4 rounds AC, 4 weekly Paclitaxol.
Mastectomy & axillary clearance 8/09. No nodal involvement. 25 doses rads.
2 more rounds of A/C, 6 months low-dose CMF.
|
|
Susie
Senior Member
Joined: May 12 2010
Location: Birmingham,Al
Status: Offline
Points: 212
|
Post Options
Thanks(0)
Quote Reply
Posted: Feb 07 2011 at 7:20am |
Good news which I hope is true, since I took it by IV once per month for a year!
|
dx 10/08,age 56,.75 cm. Stage1 Grade3,lumpectomy,SN neg..,AC 12/08-02/09,35rads,03/09-05/09,BRCA2+(E1415X),06/09,oophorectomy 10/09,
Zometa - IV/mo.,07/09-08/10, lumpectomy #2 10/20/10 NED
|
|
123Donna
Senior Member
Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 13509
|
Post Options
Thanks(0)
Quote Reply
Posted: May 07 2018 at 9:25pm |
Osteoporosis Drug Has Potential To Fight Triple Negative Breast CancerMedicalResearch.com Interview with: Chenfang Dong, Ph.D & M.D. Professor Department of Pathology and Pathophysiology Zhejiang University School of Medicine, MedicalResearch.com: What is the background for this study? What are the main findings? Response: Basal-like breast cancer (BLBC), which generally falls into the triple-negative breast cancer subtype, is associated with a poor clinical outcome due to few treatment options and poor therapeutic response; thus there is a pressing need to elucidate the determinants of aggressiveness in BLBC and identify potential therapeutic targets for this challenging disease. By analyzing gene expression profiles of breast cancer in multiple publicly available datasets that contain over 5000 cases, we have identified that UDP-galactose ceramide galactosyltransferase (UGT8), a key enzyme in the sulfatide biosynthetic pathway, promotes BLBC progression by activating sulfatide-αVβ5 axis. Importantly, we identify that zoledronic acid (ZA), a marketed drug for treating osteoporosis and bone metastasis, is a direct inhibitor of UGT8, which has the potential to become a valuable targeted drug for treating Basal-like breast cancer. MedicalResearch.com: What should readers take away from your report? Response: Our study reveals several mechanistic and therapeutic insights into the crucial roles of UGT8 in BLBC progression. Most importantly, zoledronic acid is identified as a direct UGT8 inhibitor, which exhibits apparent inhibitory effect on Basal-like breast cancer using cellular and mice models, suggesting that ZA has the potential to become a potential targeted drug. MedicalResearch.com: What recommendations do you have for future research as a result of this work? Response: Our study strongly supports the translational value of zoledronic acidas a direct inhibitor of UGT8. Many clinical trials have been carried out to investigate the potential anticancer activity of ZA; however few clinical trials mainly focus on triple-negative breast cancer (TNBC) or Basal-like breast cancer. Recently, two retrospective studies from randomized trials of ZA plus chemotherapy versus chemotherapy alone demonstrated that a trend favoring ZA treatment was observed in TNBC that is mostly also BLBC despite relatively small sample size of TNBC patients in both studies (including 34 and 103 cases, respectively). Thus, TNBC or BLBC might be the most promising subtype to be effectively treated with additional zoledronic acid. Further clinical trials that focus on TNBC or BLBC are required to assess its druggability for t
|
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09) 11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15
|
|